Literature DB >> 2817848

Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.

T I Nicas1, C T Cole, D A Preston, A A Schabel, R Nagarajan.   

Abstract

Gram-positive bacteria resistant to vancomycin are rare; but they include members of the genera Leuconostoc, Lactobacillus, and Pediococcus, as well as recently emerging vancomycin-resistant strains of Enterococcus faecium and Enterococcus faecalis. Vancomycin, teicoplanin, and several vancomycin derivatives were tested for their activities against vancomycin-resistant gram-positive bacteria. Vancomycin-resistant E. faecium and E. faecalis were generally cross-resistant to other glycopeptides, but some N-substituted vancomycin derivatives were active against the resistant strains, with MICs of 2 to 32 micrograms/ml. These vancomycin derivatives also had significant levels of activity against intrinsically vancomycin-resistant organisms such as Leuconostoc sp. While vancomycin resistance in E. faecium and E. faecalis was inducible, resistance in members of the genera Leuconostoc, Lactobacillus, and Pediococcus appeared to be expressed constitutively. Antibody to a vancomycin-induced membrane protein found in membranes of resistant enterococci did not detect a cross-reacting protein in other vancomycin-resistant species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817848      PMCID: PMC172686          DOI: 10.1128/AAC.33.9.1477

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Peptidoglycan types of bacterial cell walls and their taxonomic implications.

Authors:  K H Schleifer; O Kandler
Journal:  Bacteriol Rev       Date:  1972-12

2.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

3.  Leuconostoc, an emerging vancomycin-resistant pathogen.

Authors:  H W Horowitz; S Handwerger; K G van Horn; G P Wormser
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

4.  Vancomycin-resistant leuconostocs, lactobacilli and now pediococci.

Authors:  G Colman; A Efstratiou
Journal:  J Hosp Infect       Date:  1987-07       Impact factor: 3.926

5.  Drug resistance plasmids in Lactobacillus acidophilus and Lactobacillus reuteri.

Authors:  M Vescovo; L Morelli; V Bottazzi
Journal:  Appl Environ Microbiol       Date:  1982-01       Impact factor: 4.792

Review 6.  The enterococcus: "putting the bug in our ears".

Authors:  S A Hoffmann; R C Moellering
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

7.  Meningitis caused by vancomycin-resistant Leuconostoc sp.

Authors:  Y M Coovadia; Z Solwa; J van den Ende
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

8.  Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products.

Authors:  A Malabarba; P Strazzolini; A Depaoli; M Landi; M Berti; B Cavalleri
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

9.  Common occurrence of plasmid DNA and vancomycin resistance in Leuconostoc spp.

Authors:  P K Orberg; W E Sandine
Journal:  Appl Environ Microbiol       Date:  1984-12       Impact factor: 4.792

10.  Vancomycin-resistant streptococci or Leuconostoc sp.

Authors:  A Buu-Hoï; C Branger; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  21 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Antibacterial activities and modes of action of vancomycin and related glycopeptides.

Authors:  R Nagarajan
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 5.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Brain abscess due to Wolinella recta and Streptococcus intermedius.

Authors:  T J Marrie; E Kerr
Journal:  Can J Infect Dis       Date:  1990

7.  Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.

Authors:  S Dutka-Malen; R Leclercq; V Coutant; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 8.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.

Authors:  K V Singh; T M Coque; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

10.  In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.

Authors:  M L Sanchez; R P Wenzel; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.